Genmab — Oktober 2018

[kkjoel]

Slut herfra.

[kkjoel]

Tallene står vist bedre således:

[kkjoel]

17.10.2000, 233, +667, 8% / 17.10.2001, 125, +775, 12,5% / 17.10.2002, 32, +868, 16% / 17.10.2003, 62, +838, 19,5% / 17.10.2004, 88, +812, 14% / 17.10.2005, 129, +771, 15% / 17.10.2006, 249, +651, 8,5% / 17.10.2007, 370, +530, 8,5% / 17.10.2008, 235, +665, 14% / 17.10.2009, 141, +759, 23% / 17.10.2010, 71, +829, 37,5% / 17.10.2011, 32, +868, 61% / 17.10.2012, 87, +813, 47,5% / 17.10.2013, 239, +661, 30,5% / 17.10.2014, 232, +668, 40,5% /

[kkjoel]

17.10.2015, 628, +272, 9% / 17.10.2016, 1117, -217, -9% / 17.10.2017, 1346, -446, -33% / 17.10.2018, 900

[Jazzz]

Har osse selv været godt tilfreds med min forrentning.. rentes rente..ca 20% om året i 13 år. Eller ca.
1025% totalt..

[JKY_VH]

er også et stort ?

[E_L]

Daratumumab binds to mobilized
CD34+
cells of myeloma patients in vitro
without cytotoxicity or impaired progenitor cell
https://link.springer.com/article/10.1186%2Fs40164-018-0119-4 or in PDF https://www.readcube.com/articles/10.1186/s40164-018-0119-4
growth

[E_L]

Conclusion:

In vitro, daratumumab is not toxic to mobilized CD34+ progenitor cells from myeloma patients.

[E_L]

that is the only sentence i understand (a bit) in this article, but it sounds positive, no?

[Bulder]

Well, a tough one. As I understand it cd34+ progenitor cells are the cells you take out under an asct and then put back after high dose chemo. Now if dara was to used as maintenance after asct it wouldn't be nice if dara was toxic to these cells, as they also - besides cd34 -express cd38. This with all kinds of precaution.

[E_L]

ok, thks, that would make a lot of sense

[Bulder]

One of dara's advantages is that it activates the complement system - one of our immune mechanisms - but they seem to have found out that cdc didn't occur in this situation. Lucky for the progenitor cells (and their owner).

[E_L]

this AL Amyloidosis trial seems fully recruited: set to Active, not recruiting, Primary Completion date delayed a bit to December 2018 https://clinicaltrials.gov/ct2/history/NCT02816476?A=2&B=3&C=merged

[Hugininvest]

Kkjoel din facon er fuldt ud lige så god som andres og iøvrigt meget enig. Lige nu er der bare ingen der gider kommentere på fejlagtige eller misforståede påstande om Gens strategi og satsninger

[Helge_LarsenPI-redaktør]

Tak Stroka. Længere er den vist ikke. http://www.proinvestor.com/debat/76393#postdiv76397

[Helge_LarsenPI-redaktør]

Græsset er grønnere hos naboen lige for øjeblikket. Fred være med det.

[Helge_LarsenPI-redaktør]

Servicemeddelse: Næste Q&A er den 21. november. Genmab har accepteret mit ønske om 45 minutter i stedet for de sædvanlige 30.

[Solsen]

Super Helge. Så må vi se at få samlet spørgsmålene.

[Helge_LarsenPI-redaktør]

Jeps.

[nohope]

Spørgsmål af i dag kan hurtigt blive irrelevante - hvis MAIA viser sig inden 21/11